{"filing":{"accession_number":"0001193125-26-336681","cik":"0001826457","ticker":"GLUE","company_name":"Monte Rosa Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"glue-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826457/000119312526336681/glue-20260806.htm"},"events":[{"id":25536,"run_id":23179,"accession_number":"0001193125-26-336681","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Monte Rosa Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 6, 2026. The disclosure includes quarterly financial metrics (collaboration revenue of $9.0 million, R\u0026D expenses of $48.0 million, G\u0026A expenses of $10.1 million, net loss of $43.4 million) and cash position ($626.0 million), along with business highlights and clinical program updates. This is a standard quarterly earnings release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26393,"accession_number":"0001193125-26-336681","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Monte Rosa Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 6, 2026. The disclosure includes quarterly financial metrics (collaboration revenue of $9.0 million, R\u0026D expenses of $48.0 million, G\u0026A expenses of $10.1 million, net loss of $43.4 million) and cash position ($626.0 million), along with business highlights and clinical program updates. This is a standard quarterly earnings release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:49.620060+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26393,"accession_number":"0001193125-26-336681","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Monte Rosa Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 6, 2026. The disclosure includes quarterly financial metrics (collaboration revenue of $9.0 million, R\u0026D expenses of $48.0 million, G\u0026A expenses of $10.1 million, net loss of $43.4 million) and cash position ($626.0 million), along with business highlights and clinical program updates. This is a standard quarterly earnings release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:52:49.620060+00:00","company_name":"Monte Rosa Therapeutics, Inc.","ticker":"GLUE","filing_date":"2026-08-06"}]}